Loading...
•
Mar 31, 2025
•/
Canopy Growth Q4 2025 Earnings Report
Canopy Growth reported a net loss of $221.5 million and revenue of $65.0 million in Q4 2025.
Key Takeaways
Canopy Growth faced an 11% revenue decline in Q4 2025 compared to the same period last year, primarily due to weaker international and Storz & Bickel sales. Despite this, the company made progress in reducing operating losses and continues executing on cost-saving strategies.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company plans to accelerate growth in global medical cannabis, streamline Canadian adult-use operations, and launch new Storz & Bickel products while targeting positive Adjusted EBITDA.
Positive Outlook
- Global medical cannabis operations unified under one business unit
- Focus on high-margin, high-THC formats in Canada
- Targeting improved gross margin and profitability
- Expected annualized cost savings of $20M from SG&A and COGS reductions
- Launch of new Storz & Bickel device expected later in FY2026
Challenges Ahead
- Ongoing macroeconomic uncertainty
- Soft consumer demand for vaporizers
- Regulatory challenges in markets like Poland
- Declines in Australia medical cannabis sales
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...